Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CABRAMET cabozantinib in metastatic renal cell carcinoma with brain metastases
2019-000678-41Phase 2Active
- Sponsor
- Centre Léon Bérard
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cabozantinib in metastatic renal cell carcinoma (mRCC), sponsored by Centre Léon Bérard. Primary endpoint: Non progression rate in brain metastases at 3 months. Started Mar 2019; status: active.
02
Drugs
cabozantinib
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on 2019-000678-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000678-41.